What type of study is this?

September 5, 2025Neuro-Oncology AdvancesOpen Access

50 Influence of Kras Mutations on Treatment Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastasis Treated With Stereotactic Radiosurgery

View Full Paper

Ask AI

Bookmark

KRAS+ lung cancer patients with brain metastasis show similar recurrence rates to KRAS- patients.
Of the 161 patients, 40% presented with single brain metastases, with similar salvage treatment use across KRAS variants.
Statistical analysis revealed biological effective dose as a significant prognostic factor for CNS progression-free survival.
Results indicate the need for further studies on KRAS inhibitors and stereotactic radiosurgery's impact on outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis reveals similar outcomes between KRAS+ and KRAS- non-small cell lung cancer patients, suggesting implications for treatment strategies.

Cite This Study

Karim et al. (2025) studied this question.

synapsesocial.com/papers/68bb46b56d6d5674bccfe701 https://doi.org/10.1093/noajnl/vdaf166.047

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals similar outcomes between KRAS+ and KRAS- non-small cell lung cancer patients, suggesting implications for treatment strategies.

50 Influence of Kras Mutations on Treatment Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastasis Treated With Stereotactic Radiosurgery

Key Points

Discussion

Implication

Cite This Study

50 Influence of Kras Mutations on Treatment Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastasis Treated With Stereotactic Radiosurgery

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider